▎ 摘　　要

The PI3K-AKT-mTOR pathway plays an important role in tumor cell growth, invasion, migration and apoptosis. A blockade of this signaling pathway has arisen as a compelling target for the tumor therapy. However, there is cross-talking between different signal pathways. Combined treatment of tumors with different signal pathway inhibitors is considered as an efficient strategy for cancer therapy. NVP-BEZ235 is a dual pan-class I PI3K and mTOR kinase inhibitor currently in clinical trial. TNF-alpha is involved in the regulation of cell apoptosis. In the current work, we explored the combined use of BEZ235 and TNF-alpha on the PIK3CA mutant colorectal cancer (CRC) cell proliferation inhibition. In our strategy, the BEZ235 is loaded on PEGylated graphene oxide (GO-PEG) by physisorption via pi-pi stacking to enhance its aqueous solubility. The resulting GO-BEZ235 complex exhibited excellent aqueous solubility while retaining a high cancer cell killing potency. The combination of BEZ235 and TNF-alpha shows an enhanced cellular proliferation inhibition for HCT 116 through enhancing the G1 phase arrest and cell apoptosis compared to either drug alone. Moreover, our experiments reveal that the enhanced tumor cell apoptosis depends on the activation of caspase-9, caspase-8 and caspase-3 mediated by the increased phosphorylation level of JNK. Taken together, our findings demonstrate for the first time the feasibility of BEZ235 delivered by GO-PEG and of the combined use of BEZ235 and TNF-alpha for PIK3CA mutant CRC therapy.